Topical ocular reproxalap improved ocular dryness more than vehicle in the first part of a phase 3 trial, Aldeyra Therapeutics announced in a press release.
The ongoing, adaptive, two-part, multicenter, randomized, vehicle-controlled, double-masked, parallel-group phase 3 RENEW trial compared 0.25% topical ocular reproxalap, a novel, small-molecule immune-modulating covalent inhibitor of reactive aldehyde species, and vehicle in patients with moderate to severe dry eye disease.
The study’s first part, which included 422 subjects, aimed to confirm dosing regimen, endpoints and sample size
Uncategorized